Principles of Practice from the European Expert Panel on the Contemporary Treatment of Schizophrenia
暂无分享,去创建一个
J. Os | N. Tarrier | J. Bobes | S. Kasper | D. Naber | D. Owens | J. Gerlach | J. Hellewell | A. Altamura | J. Hellewell | Siegfried Kasper | J. Bobes | Dieter Naber | Nicholas Tarrier | Jes Gerlach
[1] A. Mitchell,et al. Cognitive-behavioural therapy for schizophrenia. , 2002, The British journal of psychiatry : the journal of mental science.
[2] S. Francey,et al. Cognitively oriented psychotherapy for early psychosis (COPE): a 1-year follow-up. , 2001, The British journal of clinical psychology.
[3] L. Merinder. Patient education in schizophrenia: a review , 2000, Acta psychiatrica Scandinavica.
[4] L. Dixon,et al. Update on family psychoeducation for schizophrenia. , 2000, Schizophrenia bulletin.
[5] S. Kasper,et al. Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia , 1999, European Archives of Psychiatry and Clinical Neuroscience.
[6] A. Altamura,et al. HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment , 1999, European Neuropsychopharmacology.
[7] R. Murray,et al. To what extent does symptomatic improvement result in better outcome in psychotic illness? , 1999, Psychological Medicine.
[8] J. Hellewell,et al. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. , 1999, The Journal of clinical psychiatry.
[9] N. Tarrier,et al. Randomised controlled effectiveness trial of a needs-based psychosocial intervention service for carers of people with schizophrenia , 1999, British Journal of Psychiatry.
[10] S. Roose. Tolerability and patient compliance. , 1999, The Journal of clinical psychiatry.
[11] J. McKellar,et al. Patient satisfaction and acceptability of long-term treatment with quetiapine. , 1999, International journal of psychiatry in clinical practice.
[12] S. Patten,et al. Depression in people with first-episode schizophrenia , 1998, British Journal of Psychiatry.
[13] R. Tandon,et al. New atypical antipsychotic medications. , 1998, Journal of psychiatric research.
[14] R. Tandon,et al. Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia? , 1998, Journal of psychiatric research.
[15] D. King. Drug treatment of the negative symptoms of schizophrenia , 1998, European Neuropsychopharmacology.
[16] I. Bitter,et al. Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy. , 1997, International journal of psychiatry in clinical practice.
[17] A. David,et al. Compliance Therapy: An Intervention Targeting Insight and Treatment Adherence in Psychotic Patients , 1996, Behavioural and Cognitive Psychotherapy.
[18] Altamura Ac. Novel antipsychotics and the problem of clinical stabilization in schizophrenia: are they "stabilizer" rather than typical compounds? , 1996 .
[19] A. Altamura. Novel antipsychotics and the problem of clinical stabilization in schizophrenia: are they “stabilizer” rather than typical compounds? , 1996, International clinical psychopharmacology.
[20] D. Penn,et al. Research update on the psychosocial treatment of schizophrenia. , 1996, The American journal of psychiatry.
[21] P. Hayward,et al. Compliance therapy in psychotic patients: randomised controlled trial , 1996, BMJ.
[22] P. Bebbington. The content and context of compliance , 1995, International clinical psychopharmacology.
[23] C. Bell. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders , 1994 .
[24] N. Tarrier,et al. A Trial of Two Cognitive-Behavioural Methods of Treating Drug-Resistant Residual Psychotic Symptoms in Schizophrenic Patients: I. Outcome , 1993, British Journal of Psychiatry.
[25] A. Altamura. A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia With particular reference to drug resistance , 1993, Schizophrenia Research.
[26] John M. Davis,et al. MAINTENANCE ANTIPSYCHOTIC MEDICATION , 1993 .
[27] T. Barnes,et al. THE SIDE-EFFECTS OF ANTIPSYCHOTIC DRUGS. I. CNS AND NEUROMUSCULAR EFFECTS , 1993 .
[28] W. Iacono,et al. Establishing the onset of psychotic illness. , 1993, The American journal of psychiatry.
[29] J. Lieberman,et al. Duration of psychosis and outcome in first-episode schizophrenia. , 1992, The American journal of psychiatry.
[30] A. Korten,et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. , 1992, Psychological medicine. Monograph supplement.
[31] A. Rifkin,et al. Dosage of haloperidol for schizophrenia. , 1991, Archives of general psychiatry.
[32] S. Marder,et al. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. , 1990, Archives of general psychiatry.
[33] L. Helgason. Twenty years’ follow‐up of first psychiatric presentation for schizophrenia: what could have been prevented? , 1990, Acta psychiatrica Scandinavica.
[34] G Honigfeld,et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.
[35] Martin H. Teicher,et al. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. , 1988, Archives of general psychiatry.
[36] T. Crow,et al. The Northwick Park Study of First Episodes of Schizophrenia , 1986, British Journal of Psychiatry.